November 19, 2020
Authored and Edited by Kathryn R. Judson; Susan Y. Tull
On November 9, 2020, FDA issued final guidance on “Enhancing the Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trail Designs,” which was first issued as draft guidance in June 2019. FDA intends for the guidance to provide sponsors with recommendations and approaches to help broaden eligibility criteria and improve clinical trial recruitment.
The guidance highlights the importance of broadening eligibility criteria during clinical trials and moving away from “commonly accepted” exclusions of certain populations, including older adults, children, patients with physical and/or mental disabilities, and those with malignancies or certain infections. FDA warns that unnecessary exclusions of such participants could lead to a failure to discover important drug safety information.
FDA recommends two approaches to help broaden eligibility criteria and increase diversity in enrollment. First, FDA encourages inclusive trial practices by enrolling participants across all clinically relevant populations. Second, FDA recommends that sponsors should consider various trial designs and methodological approaches to enroll participants of a broader population, for example, adaptive clinical trials.
In addition, FDA provides other recommendations for improving enrollment by making trial participation less burdensome for participants, adopting practices that enhance inclusiveness, and taking advantage of FDA’s expanded access regulations. The guidance concludes with discussing the current challenges faced for clinical trials involving drugs that treat rare diseases. FDA recommends additional approaches to broaden eligibility, such as engaging with patient advocacy groups on trial design and re-enrolling participants from early-phase trials into later-phase trials.
Readers are encouraged to read the final guidance, also available on FDA’s website.
Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
INCONTESTABLE® Blog
April 19, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.